Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation

Juan Liu, Yiyun Shen, Jie Liu, Dandan Xu, Chun-Yuan Chang, Jianming Wang, Jason Zhou, Bruce G. Haffty, Lanjing Zhang, Jill Bargonetti, Subhajyoti De, Wenwei Hu () and Zhaohui Feng ()
Additional contact information
Juan Liu: Rutgers-State University of New Jersey
Yiyun Shen: Rutgers-State University of New Jersey
Jie Liu: Rutgers-State University of New Jersey
Dandan Xu: Rutgers-State University of New Jersey
Chun-Yuan Chang: Rutgers-State University of New Jersey
Jianming Wang: Rutgers-State University of New Jersey
Jason Zhou: Rutgers-State University of New Jersey
Bruce G. Haffty: Rutgers-State University of New Jersey
Lanjing Zhang: Princeton Medical Center
Jill Bargonetti: City University of New York
Subhajyoti De: Rutgers-State University of New Jersey
Wenwei Hu: Rutgers-State University of New Jersey
Zhaohui Feng: Rutgers-State University of New Jersey

Nature Communications, 2025, vol. 16, issue 1, 1-18

Abstract: Abstract The tumor-suppressive function of p53 is frequently disrupted by mutations in cancers. Missense mutant p53 (mutp53) protein often stabilizes and accumulates to high levels in cancers to promote tumorigenesis through the gain-of-function (GOF) mechanism. Currently, the mechanism of mutp53 accumulation and GOF is incompletely understood. Here, we identify the lipogenic enzyme FASN as an important regulator of mutp53 accumulation and GOF. FASN interacts with mutp53 to enhance mutp53 palmitoylation, which inhibits mutp53 ubiquitination to promote mutp53 accumulation and GOF. Blocking FASN genetically or by small-molecule inhibitors suppresses mutp53 palmitoylation to inhibit mutp53 accumulation, which in turn inhibits the growth of mutp53 tumors in orthotopic and subcutaneous xenograft tumor models and transgenic mice, as well as the growth of human tumor organoids carrying mutp53. Our results reveal that mutp53 palmitoylation is an important mechanism underlying mutp53 accumulation and GOF, and targeting FASN is a potential therapeutic strategy for cancers carrying mutp53.

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-57099-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57099-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-57099-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().